NCT00575887View on ClinicalTrials.gov

Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
GlioblastomaAstrocytomaOligodendrogliomaBrain Tumor, Recurrent
Interventions
DRUG

Temozolomide

100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity

Trial Locations (1)

34660

Marmara University Hospital, Istanbul

Sponsors

Lead Sponsor

Marmara University

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Marmara University

OTHER